Role of Inflammatory Markers in Sepsis

Completed

• Conditions: Diagnostic

• Registration Number: NCT06111963
• Lead Sponsor: National Cancer Institute, Egypt

Brief Summary

A diagnostic and prognostic study, in which the expression of CD64 in activated neutrophils and CD64 and IL17A regulatory T cells in patients with sepsis will be evaluated as a probable marker for sepsis as a primary objective

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-10-16
• Study First Submitted QC: 2023-10-26
• Study Start: 2023-11-01
• Study First Posted: 2023-11-01
• Primary Completion: 2025-01-05
• Study Completion: 2025-01-25
• Status Verified: 2025-07
• Last Update Submitted: 2025-07-11
• Last Update Posted: 2025-07-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Cancer patients admitted to the surgical ICU following cancer related surgeries and diagnosed with sepsis

Exclusion Criteria

• Refusal of patient or patient guardian to participate.
• Intraoperative massive blood loss and massive blood transfusion
• Patients with impaired preoperative kidney or liver function tests

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the expression IL17	7 days	Serology
To evaluate the expression CD25	7 days	Serology
To evaluate the expression CD4	7 days	Serology

Trial Locations

Locations (1)

Walaa Y Elsabeeny; 🇪🇬 Cairo, Egypt